Popularity #717Earnings are out
Abivax (ADR) (ABVX)
Develops oral obefazimod for ulcerative colitis and Crohn's disease.
$98.54
After hours+0.27 (+0.27%)
At close$98.27(−5.01%)
Something off on this page? Send us feedback.
Next report
Dec 21, 26
estimated · in 90 days
EPS estimate
−$0.81
Revenue estimate
$794.4K
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25Jun '25Sep '25Dec '25Mar '26May '26Sep '26Dec '26
Reported−$1.68−$0.97−$0.86−$2.47−$1.19−$0.71−$1.71Pending
Estimate−$1.59−$0.76−$0.90−$0.79−$1.70−$1.07−$0.92−$0.81
Surprise−5.8%−28.3%+4.4%−214.3%+30.0%+33.6%−86.5%—
RevenueReportedEstimate
Mar '25Jun '25Sep '25Dec '25Mar '26May '26Sep '26Dec '26
Reported$6.4M$1.2M$1.3M$2.4M$515.1K$1.5M$1.4MPending
Estimate$2.8M$3.3M$1.4M$1.3M$1.8M$401.1K$799.2K$794.4K
Surprise+125.0%−65.3%−4.1%+78.5%−71.4%+277.3%+72.0%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2029 | −$1.41 | — | — |
| Sep 2029 | −$1.41 | — | — |
| Jun 2029 | −$1.47 | — | — |
| Mar 2029 | −$1.50 | — | — |
| Dec 2028 | −$1.51 | — | — |
| Sep 2028 | −$1.49 | — | — |
| Jun 2028 | −$1.52 | — | — |
| Mar 2028 | −$1.55 | — | — |
| Dec 2027 | −$1.23 | — | — |
| Sep 2027 | −$1.17 | — | — |
| Jun 2027 | −$0.92 | — | — |
| Mar 2027 | −$1.16 | — | — |
| Dec 2026 | −$0.84 | — | — |
| Dec 2026 | −$0.81 | — | — |
| Sep 2026 | −$0.92 | −$1.71 | −86.5% |
| May 2026 | −$1.07 | −$0.71 | +33.6% |
| Mar 2026 | −$1.70 | −$1.19 | +30.0% |
| Dec 2025 | −$0.79 | −$2.47 | −214.3% |
| Sep 2025 | |||
| Jun 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Sep 2024 | |||
| Apr 2024 | |||
| Sep 2023 | |||
| Jun 2023 | |||
| Apr 2023 | −$1.93 | — | — |
| Dec 2022 | |||
| Sep 2022 | |||
| Jun 2022 | |||
| Mar 2022 | |||
| Dec 2021 | |||
| Sep 2021 | |||
| Jun 2021 | |||
| Mar 2021 | |||
| Dec 2020 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Dec 2019 | |||
| Jun 2019 | |||
| Dec 2018 | |||
| Jun 2018 | |||
| Dec 2017 | |||
| Jun 2017 | |||
| Dec 2016 | |||
| Jun 2016 | |||
| Dec 2015 | |||
| Jun 2015 | |||
| Dec 2014 | |||
| Jun 2014 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2029 | −$1.41 | — | — | $0 | — | — | — |
| Sep 2029 | −$1.41 | — | — | −$4.7M | — | — | — |
| Jun 2029 | −$1.47 | — | — | $0 | — | — | — |
| Mar 2029 | −$1.50 | — | — | −$4.2M | — | — | — |
| Dec 2028 | −$1.51 | — | — | $0 | — | — | — |
| Sep 2028 | −$1.49 | — | — | −$3.7M | — | — | — |
| Jun 2028 | −$1.52 | — | — | $0 | — | — | — |
| Mar 2028 | −$1.55 | — | — | −$3.3M | — | — | — |
| Dec 2027 | −$1.23 | — | — | $2.6M | — | — | — |
| Sep 2027 | −$1.17 | — | — | $39.8M | — | — | — |
| Jun 2027 | −$0.92 | — | — | $792.9K | — | — | — |
| Mar 2027 | −$1.16 | — | — | $719.3K | — | — | — |
| Dec 2026 | −$0.84 | — | — | $792.9K | — | — | — |
| Dec 21, 2026 | −$0.81 | — | — | $794.4K | — | — | — |
| Sep 21, 2026 | −$0.92 | −$1.71 | −86.5% | $799.2K | $1.4M | +72.0% | −4.8% |
| May 22, 2026 | −$1.07 | −$0.71 | +33.6% | $401.1K | $1.5M | +277.3% | −1.6% |
| Mar 23, 2026 | −$1.70 | −$1.19 | +30.0% | $1.8M | $515.1K | −71.4% | −4.1% |
| Dec 15, 2025 | −$0.79 | −$2.47 | −214.3% | $1.3M | $2.4M | +78.5% | −5.9% |
| Sep 8, 2025 | |||||||
| Jun 2, 2025 | |||||||
| Mar 24, 2025 | |||||||
| Nov 14, 2024 | |||||||
| Sep 9, 2024 | |||||||
| Apr 2, 2024 | |||||||
| Sep 21, 2023 | |||||||
| Jun 30, 2023 | |||||||
| Apr 19, 2023 | −$1.93 | — | — | $1.3M | — | — | — |
| Dec 31, 2022 | |||||||
| Sep 15, 2022 | |||||||
| Jun 30, 2022 | |||||||
| Mar 16, 2022 | |||||||
| Dec 31, 2021 | |||||||
| Sep 23, 2021 | |||||||
| Jun 30, 2021 | |||||||
| Mar 31, 2021 | |||||||
| Dec 31, 2020 | |||||||
| Sep 24, 2020 | |||||||
| Jun 30, 2020 | |||||||
| Mar 16, 2020 | |||||||
| Dec 31, 2019 | |||||||
| Jun 30, 2019 | |||||||
| Dec 31, 2018 | |||||||
| Jun 30, 2018 | |||||||
| Dec 31, 2017 | |||||||
| Jun 30, 2017 | |||||||
| Dec 31, 2016 | |||||||
| Jun 30, 2016 | |||||||
| Dec 31, 2015 | |||||||
| Jun 30, 2015 | |||||||
| Dec 31, 2014 | |||||||
| Jun 30, 2014 |